The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Nishida, H., Hayashi, M., Morimoto, C., Sakamoto, M., & Yamada, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0127-y · Cited by 41
Bisht, K. K., Walker, B. A., Kumar, S. K., Špıčka, I., Moreau, P., Martin, T. G., Costa, L. J., Richter, J. R., Fukao, T., Macé, S., et al. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1983427 · Cited by 41
Self-citationCD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 41
Novel biomarkers in multiple myeloma
Levin, A., Hari, P., & Dhakal, B. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.003 · Cited by 41
Terpos, E., Ramasamy, K., Maouche, N., Minařík, J., Ntanasis‐Stathopoulos, I., Katodritou, E., Jenner, M. W., Plonková, H., Gavriatopoulou, M., Vallance, G. D., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03981-z · Cited by 41
Self-citationMcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Al‐Odat, O. S., Suskil, M. V., Chitren, R. J., Elbezanti, W. O., Srivastava, S. K., Budak-Alpdoǧan, T., Jonnalagadda, S. C., Aggarwal, B. B., & Pandey, M. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699629 · Cited by 42
Progress in Myeloma — A Monoclonal Breakthrough
Rajkumar, S. V., & Kyle, R. A. (2016) · New England Journal of Medicine · doi:10.1056/nejme1609835 · Cited by 40
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors
Gay, F., D’Agostino, M., Giaccone, L., Genuardi, M., Festuccia, M. B., Boccadoro, M., & Bruno, B. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.014 · Cited by 42
Multiples Myelom – aktuelle Standards in Diagnostik und Therapie
Kehrer, M., Koob, S., Strauss, A. C., Wirtz, D. C., & Schmolders, J. (2017) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/s-0043-110224 · Cited by 42
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40
Self-citationGenome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 41
Self-citationHernández‐Rivas, J., Ríos, R., Encinas, C., Alonso, R., & Lahuerta, J. J. (2022) · Biomarker Research · doi:10.1186/s40364-021-00344-2 · Cited by 40
Lulla, P. D., Tzannou, I., Vasileiou, S., Carrum, G., Ramos, C. A., Kamble, R., Wang, T., Wu, M., Bilgi, M., Gee, A. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3339 · Cited by 40
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Orlowski, R. Z., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0861 · Cited by 39
Self-citationMacEwan, J. P., Batt, K., Yin, W., Peneva, D., Sison, S., Vine, S. M., & Chen, C. C. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361035 · Cited by 39
Quality of life in multiple myeloma: considerations and recommendations
Seitzler, S., Finley-Oliver, E., Simonelli, C., & Baz, R. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1613886 · Cited by 41
Reina-Ortiz, C., Constantinides, M., de Maudave, A. F., Présumey, J., Hernández, J., Cartron, G., Giraldos, D., Díez, R., Izquierdo, I., Azaceta, G., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1853314 · Cited by 39
Takamatsu, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6100091 · Cited by 40
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
Jagannath, S., Laubach, J. P., Wong, E. Y.-M., Stockerl-Goldstein, K. E., Rosenbaum, C. A., Dhodapkar, M. V., Jou, Y., Lynch, M. J., Robbins, M. D. H., Shelat, S. G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15384 · Cited by 38
Self-citationLeBlanc, M. R., Hirschey, R., Bryant, A. L., LeBlanc, T. W., & Smith, S. K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02392-6 · Cited by 38
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 40
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Noh, J., Seo, H., Lee, J., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218000 · Cited by 40
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39
Soliman, A. M., Das, S., & Teoh, S. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147470 · Cited by 40
Advances in the treatment of extramedullary disease in multiple myeloma
Li, Y., Sun, Z., & Qu, X. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101465 · Cited by 38
Mills, J. R., & Murray, D. L. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.020784 · Cited by 37
Immunologic approaches for the treatment of multiple myeloma
Rasche, L., Weinhold, N., Morgan, G. J., van Rhee, F., & Davies, F. E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.010 · Cited by 38
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Landgren, O., Lu, S. X., & Hultcrantz, M. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.03.001 · Cited by 37
Chhabra, S., Jain, S., Wallace, C. H., Hong, F., & Liu, B. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0177-6 · Cited by 37
Chung, C. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1871 · Cited by 36
Novel Immunotherapies for Multiple Myeloma
D’Agostino, M., Boccadoro, M., & Smith, E. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0397-7 · Cited by 37
Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
Castellà, M., de Larrea, C. F., & Martín-Antonio, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113613 · Cited by 37
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
He, Y. Z., Bouwstra, R., Wiersma, V. R., de Jong, M. R. W., Lourens, H. J., Fehrmann, R. S. N., de Bruyn, M., Ammatuna, E., Huls, G. A., van Meerten, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08013-z · Cited by 36
AACR Cancer Progress Report 2016
Davidson, N. E., Armstrong, S. A., Coussens, L. M., Cruz-Correa, M. R., DeBerardinis, R. J., Doroshow, J. H., Foti, M., Hwu, P., Kensler, T. W., Morrow, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1993 · Cited by 36
Song, X., Wilson, K. L., Kagan, J., & Panjabi, S. S. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719839025 · Cited by 36
Recent Advances in the Treatment of Patients with Multiple Myeloma
Legarda, M., Cejalvo, M. J., & de la Rubia, J. (2020) · Cancers · doi:10.3390/cancers12123576 · Cited by 36
Antibody engineering and its therapeutic applications
Kandari, D., & Bhatnagar, R. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1960986 · Cited by 36
SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
Chu, E., Wu, J., Kang, S. S., & Kang, Y. (2023) · Current Oncology · doi:10.3390/curroncol30090573 · Cited by 36
Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
Sherbenou, D. W., Mark, T. M., & Forsberg, P. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.030 · Cited by 36
What is the future of immunotherapy in multiple myeloma?
Rasche, L., Hudecek, M., & Einsele, H. (2020) · Blood · doi:10.1182/blood.2019004176 · Cited by 35
Self-citationPerspectives on current and emerging therapies for immunoglobulin G4–related disease
Tanaka, Y., & Stone, J. H. (2022) · Modern Rheumatology · doi:10.1093/mr/roac141 · Cited by 35
Weng, J., Wang, Z., Hu, Z., Xu, W., Sun, J.-L., Wang, F., Zhou, Q., Liu, S., Xu, M., Xu, M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3106 · Cited by 35
Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 36
Self-citationPosttransplant maintenance therapy in multiple myeloma: the changing landscape
Sengsayadeth, S. M., Malard, F., Savani, B. N., Garderet, L., & Mohty, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.23 · Cited by 35
Maiese, E. M., Ainsworth, C., Moine, J.-G. L., Ahdesmäki, O., Bell, J. A., & Hawe, E. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.01.014 · Cited by 35
Prognostic factors for multiple myeloma in the era of novel therapies
Ziogas, D. C., Dimopoulos, M. A., & Kastritis, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1537776 · Cited by 35
Self-citationRocchi, S., Tacchetti, P., Pantani, L., Mancuso, K., Rizzello, I., Bezzi, C. D. G., Scalese, M., Dozza, L., Marzocchi, G., Martello, M., et al. (2020) · Hematological Oncology · doi:10.1002/hon.2820 · Cited by 35
SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity
Gartshteyn, Y., Askanase, A., & Mor, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654839 · Cited by 36
Lee, J. Y., Ryu, D., Lim, S. W., Ryu, K. J., Choi, M. E., Yoon, S. E., Kım, K., Park, C., & Kim, S. J. (2021) · Journal of Cancer · doi:10.7150/jca.55553 · Cited by 35
Polymeric nanomedicines targeting hematological malignancies
Gu, W., Qu, R., Meng, F., Cornelissen, J. J. L. M., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.001 · Cited by 36
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
Barankiewicz, J., Salomon‐Perzyński, A., Misiewicz-Krzemińska, I., & Lech‐Marańda, E. (2022) · Cancers · doi:10.3390/cancers14184492 · Cited by 38
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma
Vo, M.-C., Nguyen, T.-A. T., Lee, H., Nguyen-Pham, T.-N., Lakshmi, T. J., Jung, S., Kim, H., & Lee, J. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.11.004 · Cited by 35
Sagawa, M., Ohguchi, H., Harada, T., Samur, M., Tai, Y., Munshi, N. C., Kizaki, M., Hideshima, T., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0263 · Cited by 35
Self-citationOccurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma
Binder, M., Rajkumar, S. V., Ketterling, R. P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Hwa, Y. L., Zeldenrust, S. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.15 · Cited by 34
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Raza, S., Safyan, R. A., E, E. R. P., Bowman, C. A., & Lentzsch, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680548 · Cited by 34
Treating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 35
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Perrot, A., Corre, J., & Avet‐Loiseau, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200879 · Cited by 34
Detappe, A., Reidy, M., Yu, Y., Mathieu, C., Nguyen, H. V. ‐., Coroller, T. P., Lam, F. C., Jarolı́m, P., Harvey, P., Protti, A., et al. (2019) · Nanoscale · doi:10.1039/c9nr06512a · Cited by 34
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
Ho, M., Xiao, A. H., Yi, D., Zanwar, S., & Bianchi, G. (2022) · Current Oncology · doi:10.3390/curroncol29110705 · Cited by 34
Elotuzumab: First Global Approval
Markham, A. (2016) · Drugs · doi:10.1007/s40265-016-0540-0 · Cited by 34
Bock, F. M., Lu, G. G., Srour, S. A., Gaballa, S. R., Lin, H. Y., Baladandayuthapani, V., Honhar, M., Stich, M., Shah, N. D., Bashir, Q., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.003 · Cited by 34
Self-citationZhang, T., Wang, S., Wan, N., Zhang, L., Zhang, Z., & Jiang, J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.012 · Cited by 34
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
Zhou, X., Einsele, H., & Danhof, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072166 · Cited by 33
Self-citationMinařík, J., Pika, T., Radocha, J., Jungová, A., Štraub, J., Jelı́nek, T., Pour, L., Pavlíček, P., Mistrík, M., Brožová, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07732-1 · Cited by 33
Facts and Hopes in Multiple Myeloma Immunotherapy
Sperling, A. S., & Anderson, K. C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3600 · Cited by 34
Self-citationHarnessing natural killer cells for the treatment of multiple myeloma
Clara, J., & Childs, R. W. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.004 · Cited by 35
Minakata, D., Fujiwara, S., Yokoyama, D., Noguchi, A., Aoe, S., Oyama, T., Koyama, S., Murahashi, R., Nakashima, H., Hyodo, K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18654 · Cited by 35
The Role of Immunotherapy in Multiple Myeloma
Kocoglu, M. H., & Badros, A. Z. (2016) · Pharmaceuticals · doi:10.3390/ph9010003 · Cited by 32
Monoclonal antibodies in myeloma.
Sondergeld, P., van de Donk, N. W. C. J., Richardson, P. G. G., & Plesner, T. (2015) · PubMed · Cited by 32
Self-citationMechanisms of Action and Clinical Development of Elotuzumab
Ritchie, D., & Colonna, M. (2017) · Clinical and Translational Science · doi:10.1111/cts.12532 · Cited by 32
Hagen, P. A., & Stiff, P. J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.002 · Cited by 32
Novel Experimental Drugs for Treatment of Multiple Myeloma
Offidani, M., Corvatta, L., Morè, S., & Olivieri, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265288 · Cited by 32
Current approaches to management of high‐risk multiple myeloma
Goldman‐Mazur, S., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26161 · Cited by 32
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 32
New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
Mesguich, C., Zanotti‐Fregonara, P., & Hindié, E. (2015) · Theranostics · doi:10.7150/thno.14400 · Cited by 31
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 32
Self-citationMultiple Myeloma: Current Advances and Future Directions
Martin, T. G., & Huff, C. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.025 · Cited by 33
Mohyuddin, G. R., Koehn, K., Shune, L. O., Aziz, M., Abdallah, A.-O. A., McClune, B. L., Ganguly, S., McGuirk, J. P., & Kambhampati, S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1867725 · Cited by 31
DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
Saitoh, T., & Oda, T. (2021) · Cancers · doi:10.3390/cancers13030504 · Cited by 31
Dima, D., Ullah, F., Mazzoni, S. A., Williams, L. S., Faiman, B. M., Kurkowski, A., Chaulagain, C. P., Raza, S., Samaras, C. J., Valent, J. N., et al. (2023) · Cancers · doi:10.3390/cancers15072160 · Cited by 32
Gentile, M., Specchia, G., Derudas, D., Galli, M., Botta, C., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.241513 · Cited by 31
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma
Xu, L., Wen, C., Xia, J., Zhang, H., Liang, Y., & Xu, X. G. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01818-6 · Cited by 32
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 30
Salwender, H. J., Bertsch, U., Weisel, K. C., Dürig, J., Kunz, C., Benner, A., Blau, I. W., Raab, M. S., Hillengaß, J., Hose, D., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5600-x · Cited by 31
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 30
Vij, R., Nath, R., Afar, D., Mateos, M., Berdeja, J. G., Raab, M. S., Guenther, A., Martínez‐López, J., Jakubowiak, A. J., Leleu, X. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1431 · Cited by 30
Self-citationBeyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 31
Li, X., Chen, M., Wan, Y., Zhong, L., Han, X., Chen, X., Xiao, F., Liu, J., Zhang, Y., Zhu, D., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1065 · Cited by 30
Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Giralt, S. A., Jolles, S. R. A., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.05.008 · Cited by 30
Sun, Z., Zheng, F., Wu, S., Liu, Y., Guo, H., & Liu, Y. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.018 · Cited by 30
Targeting plasma cells in systemic autoimmune rheumatic diseases – Promises and pitfalls
Steinmetz, T. D., Verstappen, G. M. P. J., Suurmond, J., & Kroese, F. G. M. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.06.005 · Cited by 31
Emerging antibodies for the treatment of multiple myeloma
Zagouri, F., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1186644 · Cited by 29
Self-citationShould Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0495-9 · Cited by 29
Trudel, S., Moreau, P., & Touzeau, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s174640 · Cited by 29
Self-citationKamal, M. J., Wang, X. S., Shi, Q., Zyczynski, T. M., Davis, C., Williams, L. A., Lin, H.-K., García-González, A., Cleeland, C. S., & Orlowski, R. Z. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05493-y · Cited by 29
Self-citationChimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Dhakal, B., Hari, P., Usmani, S. Z., & Hamadani, M. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01023-w · Cited by 29
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
